| pubmed-article:7587254 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7587254 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:7587254 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:7587254 | lifeskim:mentions | umls-concept:C0699819 | lld:lifeskim |
| pubmed-article:7587254 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:7587254 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
| pubmed-article:7587254 | lifeskim:mentions | umls-concept:C0031164 | lld:lifeskim |
| pubmed-article:7587254 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:7587254 | pubmed:dateCreated | 1995-12-20 | lld:pubmed |
| pubmed-article:7587254 | pubmed:abstractText | Enhanced gut permeability has been shown in patients with advanced malignancy. The dramatic inflammatory shock syndrome produced by high-dose interleukin-2 immune therapy could further change gut barrier function. This study measured the effect of advanced renal cell carcinoma and malignant melanoma, and interleukin-2 treatment on gut permeability. | lld:pubmed |
| pubmed-article:7587254 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7587254 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7587254 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7587254 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7587254 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7587254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7587254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7587254 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7587254 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:7587254 | pubmed:issn | 0090-3493 | lld:pubmed |
| pubmed-article:7587254 | pubmed:author | pubmed-author:GelfandJ AJA | lld:pubmed |
| pubmed-article:7587254 | pubmed:author | pubmed-author:TompkinsR GRG | lld:pubmed |
| pubmed-article:7587254 | pubmed:author | pubmed-author:MierJ WJW | lld:pubmed |
| pubmed-article:7587254 | pubmed:author | pubmed-author:AtkinsM BMB | lld:pubmed |
| pubmed-article:7587254 | pubmed:author | pubmed-author:RyanC MCM | lld:pubmed |
| pubmed-article:7587254 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7587254 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:7587254 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7587254 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7587254 | pubmed:pagination | 1801-6 | lld:pubmed |
| pubmed-article:7587254 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:meshHeading | pubmed-meshheading:7587254-... | lld:pubmed |
| pubmed-article:7587254 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7587254 | pubmed:articleTitle | Effects of malignancy and interleukin-2 infusion on gut macromolecular permeability. | lld:pubmed |
| pubmed-article:7587254 | pubmed:affiliation | Surgical Service, Massachusetts General Hospital, Boston 02114, USA. | lld:pubmed |
| pubmed-article:7587254 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7587254 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7587254 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7587254 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:7587254 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7587254 | lld:pubmed |
